The Profile of Blood Sugar Level of Type 2 Diabetes Mellitus and Hyperlipidemia Patients Who Consume Oral Anti-Diabetic Drugs and Simvastatin in Some Community Health Centers in Makassar City

Metformin and glimepiride are oral anti-diabetic drugs used by diabetes mellitus patients, which aims to lower blood sugar levels, while simvastatin is an anti-hyperlipidemia drug with indications of lowering lipid levels in the blood. This study aims to determine the fasting blood sugar level during the use of a combination of oral anti-diabetic drugs and simvastatin drug for type 2 diabetes mellitus and hyperlipidemia patients in some Community Health Centers in Makassar City. This research is a descriptive non-experimental study with a treatment of data in a population of all type 2 diabetes mellitus and hyperlipidemia patients who consume oral anti-diabetic drugs and simvastatin. Data collection was conducted for a month, namely from January to February 2020, using medical record data and laboratory results of fasting blood sugar test. The research subjects consisted of 3 groups, namely metformin users (n = 39), glimepiride users (n = 13), and a combination of metformin and glimepiride users (n = 28). Changes in fasting blood sugar levels between metformin group, glimepiride group, and a combination of metformin and glimepiride group showed that during 3-month use of a combination of metformin and glimepiride, it was shown significant results (P = 0.017). This indicates that the use of a combination of metformin and glimepiride drugs is better at lowering the patients’ blood sugar level than those of a single therapy of either metformin or glimepiride. The tests were conducted to compare each group of drugs through observations in each month, and the results showed no significant difference. Thus, it can be concluded that there is no difference in any group of treatment.